Fenticonazole
Based on 4 publication(s) in Google Scholar
Fenticonazole is an imidazole derivative with antibacterial and antifungal activity. Fenticonazole has the potential for the research of mixed vaginitis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 72479-26-6
- Formel: C24H20Cl2N2OS
- Molecular Weight:455.40
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Fenticonazole
More
Biologische Aktivität
Beschreibung
Chemical Information
-
CAS. Nr. 72479-26-6
-
Molecular Weight 455.40
-
Formel C24H20Cl2N2OS
-
SMILES
ClC1=CC=C(C(Cl)=C1)C(OCC2=CC=C(SC=3C=CC=CC3)C=C2)CN4C=NC=C4
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Pharmacol Res
Identification of the anti-fungal drug fenticonazole nitrate as a novel PPARγ-modulating ligand with good therapeutic index: Structure-based screening and biological validation. [Abstract]2021 Nov:173:105860. PMID: 34461220 -
Molecules
Identification of Novel PPARγ Partial Agonists Based on Virtual Screening Strategy: In Silico and In Vitro Experimental Validation. [Abstract]2024 Oct 15;29(20):4881. PMID: 39459249 -
Bioorg Chem
Structure-based screening and biological validation of the anti-thrombotic drug-dicoumarol as a novel and potent PPARγ-modulating ligand. [Abstract]2022 Dec:129:106191. PMID: 36270169 -
BMC Cancer
Single-cell transcriptional signature-based drug repurposing and in vitro evaluation in colorectal cancer. [Abstract]2024 Mar 25;24(1):371. PMID: 38528462
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Reinheit & Dokumentation
Verweise
[1]. Tumietto F, et al. Looking for appropriateness in the cure of mixed vaginitis: the role of fenticonazole as an empiric treatment. Future Microbiol. 2019;14:1349-1355. [Content Brief]
[2]. Veronese M, et al. Fenticonazole, a new imidazole derivative with antibacterial and antifungal activity. In vitro study. Arzneimittelforschung. 1981;31(12):2133-2137. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Fenticonazole Related Classifications
HY-W115276 Related Classifications
Powered by Bioz